Wellcome Trust Makes AMR Strategic Priority After Funding O'Neill Review
Britain's well-endowed and influential Wellcome Trust which co-funded the O'Neill Review on how to tackle antimicrobial resistance has now made AMR one of its strategic priorities and aims to raise its profile with it. Wellcome policy head Ed Whiting outlines next steps in an interview with the Pink Sheet.
You may also be interested in...
The UK's recently launched AMR Centre has launched two R&D collaborations and plans two more this year.
The Pink Sheet spoke with CEOs of Zavante and Amplyx as well as a BARDA official during a roundtable discussion at the recent BIO convention about incentives for antibiotic and antifungal drug development, including a lengthy discussion of the US BARDA's CARB-X accelerator, including ideas for expanding geographically and by product type.
The globalized drugs industry needs to play ball and help find a solution to antimicrobial resistance or risk getting blamed for its failure and the resulting world health crisis.